Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study

Atherosclerosis

Volumn 217, Issue 1, 2011, Pages 263-267

  Brouwers, M C G J ^a   Troutt, J S ^b   van Greevenbroek, M M J ^a   Ferreira, I ^a,c   Feskens, E J ^d   van der Kallen, C J H ^a   Schaper, N C ^a   Schalkwijk, C G ^a   Konrad, R J ^b   Stehouwer, C D A ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b ELI LILLY AND COMPANY   (United States)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Diabetes mellitus; Dyslipidemia; Insulin resistance; PCSK9

Indexed keywords

ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; APOLIPOPROTEINS B; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; GENE EXPRESSION REGULATION; GLUCOSE; HUMANS; MALE; MIDDLE AGED; PROPROTEIN CONVERTASES; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; SERINE ENDOPEPTIDASES; TRIGLYCERIDES;

EID: 79960238532     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.03.023     Document Type: Article

References (27)

1. Ayyobi A.F., Brunzell J.D. Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. Am J Cardiol 2003, 92:27-33.
2. Malmstrom R, Packard C.J., Caslake M., et al. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 1997, 40:454-462.
3. Adiels M., Taskinen M.R., Packard C., et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006, 1-11.
4. Howard B.V., Abbott W.G., Beltz W.F., et al. Integrated study of low density lipoprotein metabolism and very low density lipoprotein metabolism in non-insulin-dependent diabetes. Metabolism 1987, 36:870-877.
5. Kissebah A.H., Alfarsi S., Evans D.J., Adams P.W. Plasma low density lipoprotein transport kinetics in noninsulin-dependent diabetes mellitus. J Clin Invest 1983, 71:655-667.
6. Duvillard L., Florentin E., Lizard G., et al. Cell surface expression of LDL receptor is decreased in type 2 diabetic patients and is normalized by insulin therapy. Diabetes Care 2003, 26:1540-1544.
7. Lambert G. Unravelling the functional significance of PCSK9. Curr Opin Lipidol 2007, 18:304-309.
8. Lakoski S.G., Lagace T.A., Cohen J.C., Horton J.D., Hobbs H.H. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009, 94:2537-2543.
9. Baass A., Dubuc G., Tremblay M., et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem 2009, 55:1637-1645.
10. Jacobs M., van Greevenbroek M.M., van der Kallen C.J., et al. Low-grade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease or severity of peripheral arterial disease: the CODAM study. Eur J Clin Invest 2009, 39:437-444.
11. Welder G., Zineh I., Pacanowski M.A., Troutt J.S., Cao G., Konrad R.J. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res 2010, 51:2714-2721.
12. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva; 1999.
13. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
14. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease study group. Ann Intern Med 1999, 130:461-470.
15. Alborn W.E., Cao G., Careskey H.E., et al. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin Chem 2007, 53:1814-1819.
16. Selvin S. Statistical analysis of epidemiological data 1996, Oxford University Press, New York.
17. Agerholm-Larsen B., Nordestgaard B.G., Steffensen R., Jensen G., Tybjaerg-Hansen A. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation 2000, 101:1907-1912.
18. Ziegler D., Pritchett Y.L., Wang F., et al. Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain. Diabetes Care 2007, 30:664-669.
19. Lambert G., Ancellin N., Charlton F., et al. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem 2008, 54:1038-1045.
20. Shin D.J., Osborne T.F. Thyroid hormone regulation and cholesterol metabolism are connected through Sterol Regulatory Element-Binding Protein-2 (SREBP-2). J Biol Chem 2003, 278:34114-34118.
21. Bakker S.J., ter Maaten J.C., Popp-Snijders C., Slaets J.P., Heine R.J., Gans R.O. The relationship between thyrotropin and low density lipoprotein cholesterol is modified by insulin sensitivity in healthy euthyroid subjects. J Clin Endocrinol Metab 2001, 86:1206-1211.
22. Sniderman A., McQueen M., Contois J., Williams K., Furberg C.D. Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?. J Clin Lipidol 2010, 4:152-155.
23. Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
24. Careskey H.E., Davis R.A., Alborn W.E., Troutt J.S., Cao G., Konrad R.J. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 2008, 49:394-398.
25. Costet P., Hoffmann M.M., Cariou B., Guyomarc'h Delasalle B., Konrad T., Winkler K. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis 2010, 212:246-251.
26. Chan D.C., Hamilton S.J., Rye K.A., et al. Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients. Diabetes Obes Metab 2010, 12:752-756.
27. Chan J.C., Piper D.E., Cao Q., et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci USA 2009, 106:9820-9825.